留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

多囊肾囊内感染与肾移植

黎雪琳 苗芸

黎雪琳, 苗芸. 多囊肾囊内感染与肾移植[J]. 器官移植, 2021, 12(2): 244-248. doi: 10.3969/j.issn.1674-7445.2021.02.018
引用本文: 黎雪琳, 苗芸. 多囊肾囊内感染与肾移植[J]. 器官移植, 2021, 12(2): 244-248. doi: 10.3969/j.issn.1674-7445.2021.02.018
Li Xuelin, Miao Yun. Intracapsular infection of polycystic kidney disease and renal transplantation[J]. ORGAN TRANSPLANTATION, 2021, 12(2): 244-248. doi: 10.3969/j.issn.1674-7445.2021.02.018
Citation: Li Xuelin, Miao Yun. Intracapsular infection of polycystic kidney disease and renal transplantation[J]. ORGAN TRANSPLANTATION, 2021, 12(2): 244-248. doi: 10.3969/j.issn.1674-7445.2021.02.018

多囊肾囊内感染与肾移植

doi: 10.3969/j.issn.1674-7445.2021.02.018
基金项目: 

国家自然科学基金 82070770

广东省自然科学基金 2020A1515010674

广州市科技计划项目 201803010109

南方医院院长基金 2018B009

南方医院院长基金 2018C003

大学生创新创业训练计划项目 202012121046

大学生创新创业训练计划项目 X202012121239

详细信息
    通讯作者:

    苗芸,女,1978年生,博士,主任医师,研究方向为肾移植,Email:miaoyunecho@126.com

  • 中图分类号: R617, R69

Intracapsular infection of polycystic kidney disease and renal transplantation

More Information
  • 摘要: 常染色体显性多囊肾病(ADPKD)是一种常见的单基因遗传性肾病,可进展为终末期肾病(ESRD)。ADPKD患者常反复发生囊内感染,抗生素治疗所产生的耐药性问题日益突出,肾移植手术方式也需根据多囊肾的感染情况进行选择。本文从肾囊肿起源、囊肿的分类及囊液的来源、囊液内细菌类型及其耐药性、ADPKD患者囊内感染与肾移植治疗等方面进行综述,为ADPKD患者囊内感染的诊治提供参考。
  • [1] BERGMANN C, GUAY-WOODFORD LM, HARRIS PC, et al. Polycystic kidney disease[J]. Nat Rev Dis Primers, 2018, 4(1): 50. DOI: 10.1038/s41572-018-0047-y.
    [2] SAITO T, TANAKA Y, MORISHITA Y, et al. Proteomic analysis of AQP11-null kidney: proximal tubular type polycystic kidney disease[J]. Biochem Biophys Rep, 2017, 13: 17-21. DOI: 10.1016/j.bbrep.2017.11.003.
    [3] TAN AY, ZHANG T, MICHAEEL A, et al. Somatic mutations in renal cyst epithelium in autosomal dominant polycystic kidney disease[J]. J Am Soc Nephrol, 2018, 29(8): 2139-2156. DOI: 10.1681/ASN.2017080878.
    [4] TSUKIYAMA T, KOBAYASHI K, NAKAYA M, et al. Monkeys mutant for PKD1 recapitulate human autosomal dominant polycystic kidney disease[J]. Nat Commun, 2019, 10(1): 5517. DOI: 10.1038/s41467-019-13398-6.
    [5] KUNNEN SJ, MALAS TB, FORMICA C, et al. Comparative transcriptomics of shear stress treated PKD1-/- cells and pre-cystic kidneys reveals pathways involved in early polycystic kidney disease[J]. Biomed Pharmacother, 2018, 108: 1123-1134. DOI: 10.1016/j.biopha.2018.07.178.
    [6] DWIVEDI N, TAO S, JAMADAR A, et al. Epithelial vasopressin type-2 receptors regulate myofibroblasts by a YAP-CCN2-dependent mechanism in polycystic kidney disease[J]. J Am Soc Nephrol, 2020, 31(8): 1697-1710. DOI: 10.1681/ASN.2020020190.
    [7] PADOVANO V, PODRINI C, BOLETTA A, et al. Metabolism and mitochondria in polycystic kidney disease research and therapy[J]. Nat Rev Nephrol, 2018, 14(11): 678-687. DOI: 10.1038/s41581-018-0051-1.
    [8] REIF GA, WALLACE DP. ADPKD cell proliferation and Cl--dependent fluid secretion[J]. Methods Cell Biol, 2019, 153: 69-92. DOI: 10.1016/bs.mcb.2019.06.001.
    [9] YANDA MK, CHA B, CEBOTARU CV, et al. Pharmacological reversal of renal cysts from secretion to absorption suggests a potential therapeutic strategy for managing autosomal dominant polycystic kidney disease[J]. J Biol Chem, 2019, 294(45): 17090-17104. DOI: 10.1074/jbc.RA119.010320.
    [10] NANTAVISHIT J, CHATSUDTHIPONG V, SOODVILAI S. Lansoprazole reduces renal cyst in polycystic kidney disease via inhibition of cell proliferation and fluid secretion[J]. Biochem Pharmacol, 2018, 154: 175-182. DOI: 10.1016/j.bcp.2018.05.005.
    [11] JANSSON K, VENUGOPAL J, SÁNCHEZ G, et al. Ouabain regulates CFTR-mediated anion secretion and Na, K-ATPase transport in ADPKD cells[J]. J Membr Biol, 2015, 248(6): 1145-1157. DOI: 10.1007/s00232-015-9832-7.
    [12] MALEKSHAHABI T, KHOSHDEL RAD N, SERRA AL, et al. Autosomal dominant polycystic kidney disease: disrupted pathways and potential therapeutic interventions[J]. J Cell Physiol, 2019, 234(8): 12451-12470. DOI: 10.1002/jcp.28094.
    [13] KENTER AT, VAN ROSSUM-FIKKERT SE, SALIH M, et al. Identifying cystogenic paracrine signaling molecules in cyst fluid of patients with polycystic kidney disease[J]. Am J Physiol Renal Physiol, 2019, 316(1): F204-F213. DOI: 10.1152/ajprenal.00470.2018.
    [14] LYU Z, MAO Z, LI Q, et al. PPARγ maintains the metabolic heterogeneity and homeostasis of renal tubules[J]. EBioMedicine, 2018, 38: 178-190. DOI: 10.1016/j.ebiom.2018.10.072.
    [15] LANKTREE MB, CHAPMAN AB. New treatment paradigms for ADPKD: moving towards precision medicine[J]. Nat Rev Nephrol, 2017, 13(12): 750-768. DOI: 10.1038/nrneph.2017.127.
    [16] HAMANOUE S, SUWABE T, UBARA Y, et al. Cyst infection in autosomal dominant polycystic kidney disease: penetration of meropenem into infected cysts[J]. BMC Nephrol, 2018, 19(1): 272. DOI: 10.1186/s12882-018-1067-2.
    [17] LANTINGA MA, DE SÉVAUX RGL, GEVERS TJG, et al. Clinical predictors of escalating care in hepatic and renal cyst infection in autosomal dominant polycystic kidney and liver disease[J]. Neth J Med, 2018, 76(5): 226-234. http://www.researchgate.net/publication/326491551_Clinical_predictors_of_escalating_care_in_hepatic_and_renal_cyst_infection_in_autosomal_dominant_polycystic_kidney_and_liver_disease
    [18] GAO C, ZHANG L, ZHANG Y, et al. Insights into cellular and molecular basis for urinary tract infection in autosomal-dominant polycystic kidney disease[J]. Am J Physiol Renal Physiol, 2017, 313(5): F1077-F1083. DOI: 10.1152/ajprenal.00279.2017.
    [19] SUWABE T, ARAOKA H, UBARA Y, et al. Cyst infection in autosomal dominant polycystic kidney disease: causative microorganisms and susceptibility to lipid-soluble antibiotics[J]. Eur J Clin Microbiol Infect Dis, 2015, 34(7): 1369-1379. DOI: 10.1007/s10096-015-2361-6.
    [20] YUAN X, LIU T, WU D, et al. Epidemiology, susceptibility, and risk factors for acquisition of MDR/XDR Gram-negative bacteria among kidney transplant recipients with urinary tract infections[J]. Infect Drug Resist, 2018, 11: 707-715. DOI: 10.2147/IDR.S163979.
    [21] LANTINGA MA, CASTELEIJN NF, GEUDENS A, et al. Management of renal cyst infection in patients with autosomal dominant polycystic kidney disease: a systematic review[J]. Nephrol Dial Transplant, 2017, 32(1): 144-150. DOI: 10.1093/ndt/gfv452.
    [22] SUWABE T, UBARA Y, HAYAMI N, et al. Factors influencing cyst infection in autosomal dominant polycystic kidney disease[J]. Nephron, 2019, 141(2): 75-86. DOI: 10.1159/000493806.
    [23] OIKONOMOU KG, ALHADDAD A. Isolation rate and clinical significance of uropathogens in positive urine cultures of hemodialysis patients[J]. J Glob Infect Dis, 2017, 9(2): 56-59. DOI: 10.4103/0974-777X.204691.
    [24] CHOE HS, LEE SJ, CHO YH, et al. Aspects of urinary tract infections and antimicrobial resistance in hospitalized urology patients in Asia: 10-year results of the Global Prevalence Study of Infections in Urology (GPIU)[J]. J Infect Chemother, 2018, 24(4): 278-283. DOI: 10.1016/j.jiac.2017.11.013.
    [25] TANDOGDU Z, CAI T, KOVES B, et al. Urinary tract infections in immunocompromised patients with diabetes, chronic kidney disease, and kidney transplant[J]. Eur Urol Focus, 2016, 2(4): 394-399. DOI: 10.1016/j.euf.2016.08.006.
    [26] JANEIRO D, PORTOLÉS J, TATO AM, et al. Peritoneal dialysis can be an option for dominant polycystic kidney disease: an observational study[J]. Perit Dial Int, 2015, 35(5): 530-536. DOI: 10.3747/pdi.2014.00029.
    [27] OH J, SHIN CI, KIM SY. Infected cyst in patients with autosomal dominant polycystic kidney disease: analysis of computed tomographic and ultrasonographic imaging features[J]. PLoS One, 2018, 13(12): e0207880. DOI: 10.1371/journal.pone.0207880.
    [28] IETTO G, RAVEGLIA V, ZANI E, et al. Pretransplant nephrectomy for large polycystic kidneys in ADPKD (autosomal dominant polycystic kidney disease) patients: is peritoneal dialysis recovery possible after surgery?[J]. Biomed Res Int, 2019: 7343182. DOI: 10.1155/2019/7343182.
    [29] VEROUX M, ZERBO D, PALMUCCI S, et al. Simultaneous nephrectomy and ipsilateral dual kidney transplantation in patients with autosomal polycystic kidney disease[J]. Transplantation, 2016, 100(1): e3-e4. DOI: 10.1097/TP.0000000000000982.
    [30] VEROUX M, GOZZO C, CORONA D, et al. Change in kidney volume after kidney transplantation in patients with autosomal polycystic kidney disease[J]. PLoS One, 2018, 13(12): e0209332. DOI: 10.1371/journal.pone.0209332.
    [31] PERICO N, CORTINOVIS M, REMUZZI G. Renal transplantation in autosomal dominant polycystic kidney disease (ADPKD)[J]. G Ital Nefrol, 2016, 33(5): gin/33.5.20.
    [32] ILLESY L, KOVÁCS DÁ, SZABÓ RP, et al. Autosomal dominant polycystic kidney disease transplant recipients after kidney transplantation: a single-center experience[J]. Transplant Proc, 2017, 49(7): 1522-1525. DOI: 10.1016/j.transproceed.2017.06.014.
    [33] MAXEINER A, BICHMANN A, OBERLÄNDER N, et al. Native nephrectomy before and after renal transplantation in patients with autosomal dominant polycystic kidney disease (ADPKD)[J]. J Clin Med, 2019, 8(10): 1622. DOI: 10.3390/jcm8101622.
  • 加载中
计量
  • 文章访问数:  15
  • HTML全文浏览量:  32
  • PDF下载量:  2
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-12-05
  • 网络出版日期:  2021-03-19
  • 刊出日期:  2021-03-15

目录

    /

    返回文章
    返回